Patient Experience

Patient Experience

CA057-001

A Phase 3, Randomized, Multicenter, Open-Label Study, Comparing CC-92480, Bortezomib and Dexamethasone (480Vd), with Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Description: This trial compares the effectiveness of 2 combination treatments (CC-92480, Bortezomib and Dexamethasone combination v's Pomalidomide, Bortezomib and Dexamethasone combination ) in patients with Relapsed or Refractory Multiple Myeloma
Study Phase: Phase 3
Principal Investigator: Dr Patrick Hayden
Further information

Isa-RVD

Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Description: This is a single arm trial assessing the effectiveness of the combination of Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Study Phase: Phase 2
Principal Investigator: Dr Patrick Hayden
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry